Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma Clinical Trial

Official title:

Bispecific NK Engager AFM13 Combined With NK Cells for Patients With Recurrent of Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04074746
• Other study ID #: 2018-1092
• Secondary ID: NCI-2019-0353620
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: July 18, 2020
• Est. completion date: April 15, 2025

Study information

• Verified date: April 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as AFM13, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving AFM13 loaded with NK cells followed by AFM13 alone may kill more cancer cells and decrease cancer growth in patients with CD30 positive AFM13-NK Hodgkin and Non-Hodgkin lymphomas.

Description:

PRIMARY OBJECTIVE:

I. To establish the safety and recommended phase II dose of umbilical cord blood (CB)-derived natural killer (NK) cells preloaded with the bispecific antibody AFM13 (AFM13-NK), followed by intravenous anti-CD30/CD16A monoclonal antibody AFM13 (AFM13) in patients with refractory/relapsed CD30-positive lymphoid malignancies based on incidence of dose limiting toxicities (DLTs) per dose level. (Phase I) II. To assess the activity of umbilical cord blood (CB)-derived natural killer (NK) cells preloaded with the bispecific antibody AFM13 (AFM13- NK), followed by intravenous AFM13 in patients with refractory/relapsed CD30-positive lymphoid malignancies. based on overall response rate (ORR), complete response (CR) rate and partial response (PR) rate. (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate the duration of response. II. To evaluate the event-free survival (EFS) rate. III. To evaluate the overall survival (OS) time. IV. To quantify the persistence of infused donor CB AFM13-NK cells in the recipient.

V. To conduct comprehensive immune reconstitution studies.

OUTLINE: This is a dose-escalation study of AFM13-NK.

Patients receive standard of care fludarabine intravenously (IV) over 1 hour and standard of care cyclophosphamide IV over 30-60 minutes on days -5 to -3, AFM13-NK IV over 4 hours on day 0, and then AFM13 IV over 4 hours on days 7, 14, and 21.

After completion of study treatment, patients are followed up at 28 days, 8 weeks, 100 and 180 days and then every 3-6 months for 2 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: April 15, 2025
• Est. primary completion date: April 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of relapsed or refractory classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), mycosis fungoides (MF), or B-cell non-Hodgkin lymphoma with a pre-enrollment tumor biopsy positive for CD30 by immunohistochemistry at >= 1%. Patients with HL, ALCL and MF must be refractory or intolerant to brentuximab vedotin.

• Karnofsky performance status >= 60%.

• Absolute neutrophil count >= 500/mm^3

• Platelet count >= 50,000/mm^3

• Serum creatinine clearance >= 50 ml/min, estimated using the Cockcroft-Gault equation.

• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN).

• Bilirubin =< 2 x ULN.

• Alkaline phosphatase (ALP) =< 2 x ULN.

• Forced expiratory volume in 1 second (FEV1) >= 50%

• Forced vital capacity (FVC) >= 50%

• Carbon monoxide diffusing capability test (DLCO) (corrected for hemoglobin [Hgb]) >= 50%

• Left ventricular ejection fraction >= 40%.

• No uncontrolled arrhythmias or symptomatic cardiac disease.

• If female of child-bearing potential, must not be pregnant or be breastfeeding and required to have a negative urine or serum pregnancy test within 3 days prior to the first dose of study drug.

• Note: Urine pregnancy tests that cannot be confirmed as negative, require a confirmatory negative serum pregnancy test. In addition, females of childbearing potential must agree use of a highly effective method of contraception for the course of the study from 14 days prior to the first dose of study drug until 60 days after the last dose of study drug. Non-childbearing potential is defined as: Postmenopausal: defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, FSH measurements indicating post-menopausal status must be documented in patient's medical history. Permanently sterile: documented permanent sterilization e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy. If male, surgically sterile or agrees to use a highly effective method of contraception, 14 days prior to the first dose of study drug until 60 days after the last dose of study drug.

Exclusion Criteria:

• Major surgery < 4 weeks prior to first dose of study drug.

• Any other severe or uncontrolled disease or condition which might increase the risk associated with study participation.

• Any other malignancy known to be active, with the exception of treated cervical intra-epithelial neoplasia and non-melanoma skin cancer.

• Grade >= 3 non-hematologic toxicity from prior therapy that has not resolved to grade =< 2.

• Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] >= 10,000 copies/mL, or >= 2,000 IU/mL), or hepatitis C (detectable viral load by hepatitis C virus [HCV] ribonucleic acid [RNA] polymerase chain reaction [PCR]).

• Active infection requiring parenteral antibiotics.

• Human immunodeficiency virus (HIV) infection.

• Treatment within prior 2 weeks with any anti-cancer agent, investigational or approved.

• Active central nervous system (CNS) involvement (untreated parenchymal brain metastasis or positive cytology of cerebrospinal fluid).

• Life expectancy =< 6 months.

• Previous treatment with AFM13.

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral
• Mycoses
• Mycosis Fungoides
• Recurrence
• Recurrent Anaplastic Large Cell Lymphoma
• Recurrent B-Cell Non-Hodgkin Lymphoma
• Recurrent Classic Hodgkin Lymphoma
• Recurrent Mycosis Fungoides
• Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Refractory Anaplastic Large Cell Lymphoma
• Refractory B-Cell Non-Hodgkin Lymphoma
• Refractory Classic Hodgkin Lymphoma
• Refractory Mycosis Fungoides
• Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

Intervention

Biological:
• Anti-CD30/CD16A Monoclonal Antibody AFM13
Given IV

Drug:
• Cyclophosphamide
Given IV
• Fludarabine
Given IV
• Fludarabine Phosphate
Given IV

Biological:
• Genetically Engineered Lymphocyte Therapy
Given AFM13-NK cells IV

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events	Adverse events will be summarized by dose.	Up to 2 years
Secondary	Overall survival	Distribution will be estimated using Kaplan-Meier method.	Up to 2 years
Secondary	Event-free survival	Distribution will be estimated using Kaplan-Meier method.	Up to 2 years
Secondary	Overall response rate (ORR)	Will be determined by ratio of responses over number of patients with measurable lesions. Logistic regression will be used to assess the association between ORR and disease and demographic covariates of interest.	Up to 2 years
Secondary	Complete response (CR) rate	Will be determined by ratio of CRs over number of patients with measurable lesions.	Up to 2 years
Secondary	Partial response (PR) rate	Will be determined by ratio of PRs over number of patients with measurable lesions.	Up to 2 years
Secondary	Duration of response		Time of initial response to disease relapse/progression, assessed up to 2 years
Secondary	Persistence of infused donor AFM13-NK cells	Will be summarized with descriptive statistics.	Up to 2 years
Secondary	Immune reconstitution studies	Will be summarized with descriptive statistics.	Up to 2 years

External Links

•   University of Texas MD Anderson Cancer Center Website